EWTX ▲ +14.4% - Edgewise Therapeutics, Inc.
$EWTX EWTX - Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
05-NOV-2026 08:01 AM ET
Share this post
More filings for $EWTX
EWTX ▲ +2.4% - Edgewise Therapeutics, Inc.Nov 4, 2026EWTX ▼ -0.5% - Edgewise Therapeutics, Inc.Nov 4, 2026EWTX ▲ +0.1% - Edgewise Therapeutics, Inc.Nov 2, 2026EWTX ▲ +1.1% - Edgewise Therapeutics, Inc.Oct 8, 2026EWTX - Edgewise Therapeutics, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $EWTX filing history →💬 Comments
Loading comments…
Leave a comment